43 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
with these third parties on acceptable terms, or if any such engagement is terminated prematurely, we may be unable to enroll patients on a timely … , consultants, contractors and other advisors execute agreements requiring non-disclosure and assignment of inventions prior to their engagement. We
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:17pm
in connection with the purchase and sale of the Company’s securities and not as a fiduciary of the Company and (c) the Company’s engagement of the Manager
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
into agreements with these third parties on acceptable terms, or if any such engagement is terminated prematurely, we may be unable to enroll patients on a timely … , consultants, contractors and other advisors execute agreements requiring non-disclosure and assignment of inventions prior to their engagement. We
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:10pm
in connection with the purchase and sale of the Company’s securities and not as a fiduciary of the Company and (c) the Company’s engagement
6-K
EX-99.1
olp6qi
22 Apr 24
XORTX Announces Publication of Key Research in ADPKD
7:00am
6-K
EX-10.1
7wv8wohdl2r8
30 Nov 23
XORTX Announces US ATM Offering
4:04pm
POS AM
EX-10.26
c816gov6
4 Aug 23
Prospectus update (post-effective amendment)
4:05pm
6-K
EX-99.2
3erh1z1ks
30 May 23
Notice of Annual & Special Meeting of Shareholders
7:00am
6-K
EX-99.3
44y9iv 1luh17xxin
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
EX-99.1
m8afm8 0z
16 Nov 22
XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer
7:29am
S-8
EX-4.2
jbfqa 2utt2y
27 Oct 22
Registration of securities for employees
7:09pm
6-K
EX-99.1
fk3ujb8
6 Oct 22
A.G.P./Alliance Global Partners
4:47pm
424B4
72ol6gzisc5r7mhf8v
5 Oct 22
Prospectus supplement with pricing info
5:24pm